Join the club for FREE to access the whole archive and other member benefits.

BIOAGE

Developing a broad pipeline of therapies to extend human healthspan and lifespan

We’re an interdisciplinary team of computational biologists, experimental scientists, and seasoned drug hunters. We share the vision that targeting aging directly, rather than targeting individual age-related diseases one at a time, will have a dramatic positive impact on human health.

The BIOAGE discovery platform leverages recent technological advances to create a deep omics map of human aging. We generate this map by applying novel machine learning and bioinformatics approaches to proprietary human cohort data to reveal the molecular drivers of age-related pathology. Our pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.

At BIOAGE, we are mapping human aging from the ground up. We have forged partnerships with unique biobanks containing healthy human samples collected over decades that are paired with extensive follow-up records that include detailed future healthspan, lifespan, and disease outcomes. We are building deep molecular profiles of these samples, incorporating proteomics, metabolomics, and transcriptomics to identify the best drug targets for healthy aging.

BIOAGE Leadership Team

Kristen Fortney, Co-Founder, CEO
Eric Morgen, Co-Founder, COO
Paul Rubin, CMO & EVP, Research

BIOAGE Metabolic Advisory Board

William J. Evans
Tim Rolph
Narimon Honarpour
Caroline Apovian
Zan Fleming
Cedric Dray

Visit website: https://bioagelabs.com/

bioage-labs

BioAgeLabs

Details last updated 28-Feb-2020

BIOAGE News

BioAge halts obesity drug trial after safety concerns

BioPharma Dive - 07-Dec-2024

Liver enzyme spikes in participants prompt a major setback for the biotech firm

Bioage prepares for IPO, targets obesity with new drug trials

FierceBiotech - 04-Sep-2024

Biotech firm Bioage plans public debut as it advances promising obesity treatments

Drug company BioAge raised $170 million to make new medicines for obesity

Longevity Technology - 13-Feb-2024

Their main drug, azelaprag, is like a pill that mimics the benefits of exercise

Lifespan.io summarises the proceedings of the Buck Institute's Longevity Summit

Lifespan.io (LEAF) - 20-Jan-2023

Another reminder of the amount of research, with multiple approaches, about to go into clinical trials

Longevity Technology speaks to BioAge's CEO about clinical trial progress

Longevity Technology - 06-Jan-2023

Had success in reducing muscle atrophy and discovered novel class of molecules to target cognitive decline

Display all news

Mentioned in this Resource

Alexander Fleming

Founder and Executive Chairman at Kinexum

Caroline Apovian

Professor of Medicine, Department of Medicine Division of Endocrinology, Diabetes and Nutrition, Brigham and Women's Hospital

Cedric Dray

Professor at the Paul Sabatier University

Eric Morgen

COO and Co-founder at BioAge Labs

Kristen Fortney

Chief Executive Officer and co-founder at BioAge

Narimon Honarpour

Senior Vice President, Global Development at Amgen

Paul Rubin

Chief Medical Officer at Bioage Labs and Pharma and biotech Consultant at Rubin Pharma

Tim Rolph

Co-founder and Chief Scientific Officer at Akero Therapeutics

William Evans

Adjunct Professor of Geriatrics in Department of Medicine at Duke University

BIOAGE is also referenced in the following:

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.